Key Metrics of ICON plc (ICLR)
Revenue$8.1B▲ 4.1% YoYFY 2023
Operating income$905M▲ 13.8% YoY
Net profit$554M▲ 9.7% YoY
Shareholders' equity$9.2B
Market cap$14.2BICLR · $185.27
Competitors10identified
About ICON plc (ICLR)
Sectors
Company details
- Founded
- 1998
- Listed
- Nasdaq: ICLR (since 1998)
Operational Areas of ICON plc (ICLR)
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameICON plc
TickerICLR
ExchangeNasdaq
CountryIreland
SEC CIK0001060955
Listed since1998
IndustryBiotechnology: Commercial Physical & Biological Resarch
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
ICLR · Nasdaq · SEC CIK 0001060955
Last price · 26 Oct 2026
$185.27
−0.09%
Market cap$14.2B
P/E27.7On FY 2023 diluted EPS
Volume1,022,577
SectorHealth CareBiotechnology: Commercial Physical & Biological Resarch
Country · IPOIrelandListed 1998
ICLR share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of ICON plc (ICLR)
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.